Gastric electrical stimulation for medically refractory gastroparesis

Diabetic Gastrointestinal Neuropathy: Elusive Diagnosis and Difficult Treatment

“…In agreement with previous studies on GES in gastroparesis [37][38][39][40] they confirmed that GES by a permanently implantable system (Enterra Therapy) significantly reduced severity and frequency of all upper GI symptoms assessed, including vomiting, nausea, early satiety, bloating, postprandial fullness, and epigastric pain, with all subscores significantly reduced at 6 and 12 months of GES. The authors argue that the statistical significance of the results, which were also accompanied by a significant improvement in the HQOL (Heath-Related Quality of life) evaluated using the previously validated SF-36 questionnaire, might depend on the larger database available for analysis in their study [41].…”

Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting - randomised clinical study subset data

“…gastric electrical stimulation and ⁄ or jejunostomy). [14][15][16] Thus, there is an unmet medical need for a well-tolerated pharmacological option that alleviates severe nausea and vomiting. TZP-101 (ulimorelin) is a first-in-class macrocyclic peptidomimetic with potent binding affinity for the ghrelin receptor, also known as the growth hormone secretagogue receptor (hGHS-R1a).…”

Treatment of gastrointestinal autonomic neuropathy

“…Gastric electrical stimulation (GES) was approved by the FDA as a Humanitarian Device exemption in patients with refractory symptoms of diabetic or idiopathic gastroparesis in 2000 based on the findings of two studies [17,18]. This approach produces the best effects on nausea and vomiting in patients with diabetic gastroparesis.…”